Log in to save to my catalogue

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and as...

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and as...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6f596cfb2e7048f7b2e60a6a21991735

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

About this item

Full title

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Publisher

England: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002535

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundThe impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and methodsE1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg...

Alternative Titles

Full title

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_6f596cfb2e7048f7b2e60a6a21991735

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6f596cfb2e7048f7b2e60a6a21991735

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2021-002535

How to access this item